AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23819226
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (2HRZE/4HRE)
Trial: 19852040
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg MMPD
Trial: 19852040
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg MMPD
Trial: 14740231
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of GSTM1 and GSTT1 null genotypes
Trial: 9197352
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of units of blood products administered during transplantation
Trial: 7968324
Drug: Intrathecal meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal meperidine (0.2 mg/kg) with spinal tetracaine (12‐16 mg)
Trial: 31705547
Drug: Insulin degludec/liraglutide
RxNorm normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin degludec/liraglutide (IDegLira)
Trial: 31903724
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 100 units/mL (IGlar U100)
Trial: 30367884
Drug: Fluocinolone acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone acetonide (FA) insert (0.18 mg)
Trial: 28963915
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab (Herceptin® SC) 600 mg fixed dose followed by intravenous trastuzumab (Herceptin®) 8 mg/kg loading, 6 mg/kg maintenance doses every 3 weeks.
Trial: 28963915
Drug: Intravenous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous trastuzumab (Herceptin®) 8 mg/kg loading, 6 mg/kg maintenance doses every 3 weeks followed by subcutaneous trastuzumab (Herceptin® SC) 600 mg fixed dose.
Trial: 22704520
Drug: 23-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent pneumococcal plain polysaccharide vaccine
Trial: 20930212
Drug: Dose‐matched therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose‐matched therapeutic exercises (DMTE)
Trial: 17141354
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine and aspart
Trial: 17141354
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin and aspart
Trial: 15099940
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (200 microg, two capsules, four times daily)
Trial: 3406455
Drug: Combined photon-low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined photon-low energy neutron treatment regimen (mixed beam)
Trial: 3406455
Drug: Conventional photon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional photon and/or electron treatment
Trial: 30890552
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg siltuximab
Trial: 26298296
Drug: HBV vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV vaccination at 20 μg (for children < 10 years) or 40 μg (for children > 10 years) at time 0, 1, and 6 months.
Trial: 26298296
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received HBV vaccination at 10 μg (for children < 10 years) or 20 μg (for children > 10 years) at time 0, 1, and 6 months.
Trial: 9783191
Drug: CMA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMA therapy for 4 weeks before LH-RH analogue injection
Trial: 9783191
Drug: CMA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMA therapy for 2 weeks before LH-RH analogue injection
Trial: 9783191
Drug: CMA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMA therapy
Trial: 30680617
Drug: 6-month program
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month program of weekly aerobic exercises associated with nutritional counseling (n = 41)
Trial: 28614869
Drug: MA212 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MA212 (40 mL daily)
Trial: 21373969
Drug: Neoadjuvant temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant temozolomide (TMZ) and 13‐cis retinoic acid (13‐cRA) treatment
Trial: 17344769
Drug: Antihypertensive medication
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive medication adherence assessment via telephone questionnaire
Trial: 9128029
Drug: Lidocaine 40
RxNorm normalized name: lidocaine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 40 mg (2 ml of lidocaine 2%) added to 180 mg of propofol (18 ml)
Trial: 9128029
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (2 ml) added to 180 mg of propofol (18 ml)
Trial: 9128029
Drug: Lidocaine 40
RxNorm normalized name: lidocaine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 40 mg premixed with 180 mg propofol
Trial: 27040503
Drug: n‐3 PUFAs,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 PUFAs, 1 g three times a day for 18 months
Trial: 25378225
Drug: 5-grass pollen
RxNorm normalized name: grass pollen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-grass pollen sublingual tablet
Trial: 15671806
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of metronidazole +/‐ 500 mg of ciprofloxacin
Trial: 12353340
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg, increased to 20 mg after 8 weeks
Trial: 12353340
Drug: Simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 mg, increased to 20 mg after 8 weeks
Trial: 10577635
Drug: Conventional antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antihypertensive drugs (atenolol 50 mg, metoprolol 100 mg, pindolol 5 mg, or hydrochlorothiazide 25 mg plus amiloride 2.5 mg daily)
Trial: 10577635
Drug: Newer antihypertensive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer antihypertensive drugs (enalapril 10 mg or lisinopril 10 mg, or felodipine 2.5 mg or isradipine 2‐5 mg daily)
Trial: 16138560
Drug: Conventional antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antihypertensive drugs
Trial: 10577635
Drug: Newer antihypertensive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer antihypertensive drugs
Trial: 8741162
Drug: Chlorpheniramine 4
RxNorm normalized name: chlorpheniramine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine 4 mg
Trial: 2987139
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (50 g) given 5 min after dextropropoxyphene hydrochloride (130 mg)
Trial: 2987139
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (50 g) followed by 12.5 g at 6 h intervals
Trial: 18346173
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg daily
Trial: 31044492
Drug: Oral tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tetracycline 250 mg bd and topical benzoyl peroxide 2.5%
Trial: 15626549
Drug: Public Health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Public Health Dose (17.5 kcal/kg/week, 3 or 5 days/week)
Trial: 15626549
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose (7.0 kcal/kg/week, 3 or 5 days/week)
Trial: 12081121
Drug: L1 group
RxNorm normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L1 group (lower limbs in neutral position when analgesic level reached L1 dermatome)
Trial: 12081121
Drug: T6 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T6 group (lower limbs in neutral position when analgesic level reached T6 dermatome)
Trial: 10208996
Drug: Corrected TIMI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corrected TIMI frame count (CTFC) measured at 90 minutes after thrombolytic administration.
Trial: 8004854
Drug: Referral to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral to nursing, social work, physiotherapy, occupational therapy, or dietary services for potential discharge planning in Hospital A
Trial: 8004854
Drug: Referral to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral to nursing, social work, physiotherapy, occupational therapy, or dietary services for potential discharge planning in Hospital B
Trial: 2599668
Drug: Keto-analogues (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keto-analogues (200 mg/kg/d) with low-protein diet (0.4 g/kg/d)
Trial: 2599668
Drug: Keto-analogues (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keto-analogues (200 mg/kg/d) with normal protein diet (1 g/kg/d)
Trial: 21659488
Drug: Sprint exercise
RxNorm normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sprint exercise (30-s Wingate test) after glucose ingestion (n = 8, G)
Trial: 18470779
Drug: Treatment program
RxNorm normalized name: ZO Skin Health Acne Prevention Plus Treatment Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment program based on evidence‐based treatments (EBTs) for disruptive behavior problems
Trial: 16508257
Drug: Probiotic yogurt
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yogurt (100 g/day for 2 weeks, then 200 g/day for 2 weeks)
Trial: 16508257
Drug: Conventional yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional yogurt (100 g/day for 2 weeks, then 200 g/day for 2 weeks)
Trial: 10925331
Drug: Small-molecule IIb/IIIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-molecule IIb/IIIa inhibitors (eptifibatide or tirofiban)
Trial: 8226583
Drug: Fenfluramine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine (1.5 mg/kg per day)
Trial: 8226583
Drug: Methylphenidate (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (0.4 mg/kg per day)
Trial: 3536644
Drug: Ensure, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensure, a defined formula dietary supplement
Trial: 22699797
Drug: PASCET-PI (Primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PASCET-PI (Primary and Secondary Control Enhancement Therapy-Physical Illness)
Trial: 16429182
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (no demineralizing agent)
Trial: 16429182
Drug: Group 3
RxNorm normalized name: Chlamydophila psittaci biogroup 3 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3 (17% EDTA solution, pH 7, for 3 min)
Trial: 16429182
Drug: Group 4
RxNorm normalized name: Chlamydophila psittaci biogroup 4 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 4 (24% EDTA gel, pH 7, for 4 min)
Trial: 12360101
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg bodyweight)
Trial: 10353855
Drug: Rimantadine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimantadine treatment
Trial: 1936109
Drug: Total Parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Parenteral Nutrition (TPN) during chemotherapy
Trial: 1936109
Drug: Spontaneous oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spontaneous oral intake only (Control)
Trial: 7287241
Drug: Amiloride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (5 mg) and Tienilic acid (250 mg)
Trial: 7287241
Drug: Triamterene (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamterene (100 mg) and Tienilic acid (250 mg)
Trial: 7287241
Drug: Amiloride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (10 mg) and Tienilic acid (250 mg)
Trial: 7287241
Drug: Triamterene (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamterene (200 mg) and Tienilic acid (250 mg)
Trial: 31261168
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of phenylephrine (P group)
Trial: 31261168
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of norepinephrine (N group)
Trial: 29028556
Drug: Intranasal methamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal methamphetamine (0, 15, and 30mg)
Trial: 22088800
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of 1 million autologous cardiac stem cells (CSCs) at a mean of 113 days after surgery.
Trial: 23596142
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (5 mg)
Trial: 7701971
Drug: Non-drug-dependent controls
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-drug-dependent controls
Trial: 3109144
Drug: Tetracycline (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (250 mg four times a day for 10 days)
Trial: 3109144
Drug: Penicillin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin (250 mg four times a day for 10 days)
Trial: 3109144
Drug: Erythromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (250 mg four times a day for 10 days)
Trial: 3109144
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous penicillin (20 million U a day for 10 days)
Trial: 3109144
Drug: Intramuscular benzathine
RxNorm normalized name: Cephapirin Benzathine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular benzathine penicillin (7.2 million U)
Trial: 3109144
Drug: Intravenous penicillin
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous penicillin G (20 million U a day for 10 days)
Trial: 29705470
Drug: Routine prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine prescription (control group)
Trial: 24440931
Drug: Cinitapride (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinitapride (1 mg)
Trial: 3922052
Drug: Nitroglycerin ointment
RxNorm normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin ointment (30 mg)
Trial: 1648849
Drug: Sodium selenite
RxNorm normalized name: Sodium selenite
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Sodium selenite therapy
Trial: 28379902
Drug: Cangrelor (Kengreal)
RxNorm normalized name: cangrelor Injection [Kengreal]
DrugBank: Cangrelor (DB06441)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cangrelor (Kengreal) administered as an intravenous infusion
Trial: 28379902
Drug: Cangrelor (Kengreal)
RxNorm normalized name: cangrelor Injection [Kengreal]
DrugBank: Cangrelor (DB06441)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cangrelor (Kengreal) as bridging therapy
Trial: 25138802
Drug: Third-wave cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-wave cognitive therapy (n=22)
Trial: 25138802
Drug: Mentalisation-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalisation-based treatment (n=22)
Trial: 23173831
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA (3g daily) for 5 weeks
Trial: 15146330
Drug: L -5-Hydroxytryptophan
RxNorm normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L -5-Hydroxytryptophan (2 mg/kg per day) administered at bedtime for 20 consecutive days
Trial: 2567178
Drug: Neostigmine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (various doses)
Trial: 9526930
Drug: Droperidol 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 1.25 mg plus ondansetron 4 mg
Trial: 7926977
Drug: Recombinant erythropoietin
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant erythropoietin (r‐EPO) administered subcutaneously at dosages up to 1050 U/kg a week for at least two months
Trial: 2512637
Drug: tenoxicam 20
RxNorm normalized name: tenoxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tenoxicam 20 mg daily
Trial: 2512637
Drug: piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piroxicam 20 mg daily
Trial: 1105630
Drug: Secobarbital (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secobarbital (100 mg)
Trial: 1105630
Drug: Secobarbital (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secobarbital (130 mg)
Trial: 1105630
Drug: CPZ (0.667
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPZ (0.667 and 1.334 mg/kg)
Trial: 1105630
Drug: Diazepam (0.071,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.071, 0.142, and 0.284 mg/kg)
Trial: 27109623
Drug: Verucerfont (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verucerfont (350 mg per day)
Trial: 19954391
Drug: Pimecrolimus 1%
RxNorm normalized name: PIMECROLIMUS 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimecrolimus 1% cream
Trial: 16503881
Drug: Control (usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (usual care with emollients and topical corticosteroids)
Trial: 12788302
Drug: Repeat fibrinolytic
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat fibrinolytic therapy
Trial: 12788302
Drug: Aggressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive treatment (repeat fibrinolysis or urgent revascularization)
Trial: 6845046
Drug: Benzoylmetronidazole 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzoylmetronidazole 50 ml (2 g metronidazole equivalent) as a single dose
Trial: 25315942
Drug: Esmolol (β-blocker)
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esmolol (β-blocker)
Trial: 27485803
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% lidocaine injection
Trial: 10670862
Drug: Open carotid
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open carotid endarterectomy with patch closure (CEAP)
Trial: 7587688
Drug: Preoperative parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative parenteral nutritional support (PNS) for 7 days in addition to oral intake
Trial: 7587688
Drug: Preoperative parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative parenteral nutritional support (PNS)
Trial: 43488
Drug: Oxprenolol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol (300 mg daily for 8 weeks)
Trial: 43488
Drug: Beta-blocking agents
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocking agents alone
Trial: 43488
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of oxprenolol and clortalidone
Trial: 43488
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of oxprenolol and phentolamine
Trial: 24721352
Drug: Penehyclidine inhalation
RxNorm normalized name: Penequinine, Penehyclidine
DrugBank: Penequinine, Penehyclidine (DB16287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penehyclidine inhalation
Trial: 31135570
Drug: VYC‐25L hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VYC‐25L hyaluronic acid injectable gel
Trial: 26938764
Drug: Dexamethasone with
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone with bupivacaine (8 mg dexamethasone mixed with 18 mL of 0.25% bupivacaine)
Trial: 26938764
Drug: Bupivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine with placebo (18 mL of 0.25% bupivacaine and 2 mL of 0.9% saline)
Trial: 23841261
Drug: Sarcandra glabra
RxNorm normalized name: SARCANDRA GLABRA TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarcandra glabra (SG) decoction at a daily dose of 20 g